Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
23 mars 2023 08h05 HE
|
Aeterna Zentaris Inc
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing...
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
17 janv. 2023 08h05 HE
|
Aeterna Zentaris Inc
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across...
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
10 janv. 2023 08h05 HE
|
Aeterna Zentaris Inc
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
29 août 2022 08h00 HE
|
Aeterna Zentaris Inc
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...
Aeterna Zentaris Announces Effective Date of Share Consolidation
18 juil. 2022 17h06 HE
|
Aeterna Zentaris Inc
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
21 juin 2022 16h01 HE
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
07 févr. 2022 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
26 janv. 2022 16h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 08h00 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a...